CAL
SYRS

Capital Analysts LLC’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Capital Analysts LLC’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-20
Closed -$2K – 823
2020
Q3 		$2K Buy
+20
New +$2.27K ﹤0.01% 719

Other funds holding SYRS

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Capital Analysts LLC's SYRS Position: Q4 2020 in Review

Capital Analysts LLC sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q4 2020, closing a stake of 20 shares — an estimated $2K sold.

Capital Analysts LLC first reported a position in SYRS in Q3 2020 and held it in 1 quarter. The position peaked at $2K in Q3 2020. 101 funds tracked by Wall St. Rank hold SYRS as of Q4 2020.

  • Capital Analysts LLC reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Capital Analysts LLC sold 20 Syros Pharmaceuticals, Inc. Common Stock shares in Q4 2020, an estimated $2K.
  • Capital Analysts LLC first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2020 and held it in 1 quarter.
  • Capital Analysts LLC's Syros Pharmaceuticals, Inc. Common Stock position peaked at $2K in Q3 2020.
  • 101 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q4 2020.

Based on Capital Analysts LLC's 13F filing for Q4 2020, filed 16 Feb 2021.